MAPT and Mental deterioration: Patients in the high cortical and striatal uptake stage (stage 2) were found to have more severe tau pathology, smaller hippocampal volume, and steeper cognitive decline and hypometabolism compared to patients in the high cortical but low striatal uptake stage (stage 1) [11,12].